EClinicalMedicine 59 , 101920 (2023)
increased corneal nerve fiber density Study Type 2 diabetes (2014) Design 4 mg subQ daily, 28 days Key result Improved neuropathic symptoms, HbA1c, lipids, nerve density Study Phase 2b sarcoidosis (2017) Design 64 patients, 1/4/8 mg subQ daily, 28 days Key result Met primary corneal nerve-regeneration endpoint
Rabbit aorta glutathione S-transferases and their role in bioactivation of trinitroglycerin
That last list is the "503A bulks list." Appearing on it is a compounding-eligibility decision it is not FDA approval of a finished drug, which is an entirely separate pathway
it does not support a clinical recommendation, including for athletes with tendon injuries
Trials conducted between 2001 and 2007 demonstrated statistically significant reductions in body fat, although the larger Phase IIb OPTIONS trial did not replicate these findings at sufficient magnitude for regulatory approval, and formal development was discontinued in 2007
